AusperBio Announces Late-Breaking 48-Week Phase II Data of AHB-137 in Chronic Hepatitis B at AASLD 2025

Pooled 48-week results from two Phase II studies show sustained antiviral responses and a favorable safety profile of AHB-137 in HBeAg-negative chronic hepatitis B patients on NA therapy. SAN FRANCISCO, Nov. 8, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co.,...